Breast cancer mortality rates among United States (US) women aged 30-79 years between 1975 and 2019.
FDA rejects Amneal’s extended-release Parkinson’s treatment, seeking more safety data
The FDA has rejected specialty pharma and generics maker Amneal Pharmaceuticals’ extended-release capsule for Parkinson’s disease, which combines two drugs that have long been used